Phytotherapy in the management of benign prostatic hyperplasia (Q34466645)

2 August 2017

1 reference

title

Phytotherapy in the management of benign prostatic hyperplasia (English)

1 reference

2 August 2017

Lowe FC

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

2 August 2017

issue

6 Suppl 1

1 reference

2 August 2017

page(s)

71-6; discussion 76-7

1 reference

Phytotherapy in the treatment of benign prostatic hyperplasia: an update

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Why patients use alternative medicine: results of a national study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Phytotherapy in treatment of benign prostatic hyperplasia: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Modification of arachidonic metabolism by flavonoids

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Inhibition in vitro of platelet aggregation and arachidonic acid metabolism by flavone

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Early urodynamic effects of the lipido-sterolic extract of Serenoa repens (Permixon(R)) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Discrepancies between Meta-Analyses and Subsequent Large Randomized, Controlled Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Effects of tadenan pretreatment on bladder physiology and biochemistry following partial outlet obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

A double-blind trial of the effect of beta-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

A systematic review of Cernilton for the treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901303-6

7 January 2021

10.1016/S0090-4295(01)01303-6

Identifiers

DOI

1 reference

2 August 2017

1 reference